Jennifer Kaivers

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

Sophie Park, Jean-François Hamel, Andréa Toma et al. · Journal of Clinical Oncology · 2017 · 99 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

EASIX for prediction of survival in lower-risk myelodysplastic syndromes

Almuth Maria Anni Merz, Ulrich Germing, Guido Kobbe et al. · Blood Cancer Journal · 2019 · 69 citations · Full text

Medicine, Hematology, Internal Medicine +17

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Esther Schuler, Eva‐Maria Wagner‐Drouet, Salem Ajib et al. · Annals of Hematology · 2020 · 67 citations · Full text

Medicine, Hematology, Oncology +12

Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study

Lisa Pleyer, Michael Leisch, Alexandra Kourakli et al. · The Lancet Haematology · 2021 · 53 citations

Medicine, Hematology, Oncology +13

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation

Christina Rautenberg, Anika Bergmann, Ulrich Germing et al. · Cancers · 2020 · 47 citations · Full text

Medicine, Hematology, Oncology +17